Clinical Trials Browser

Completed × INDUSTRY × lazertinib × Clear all

NCT04075396 2025-04-29

A Study of Lazertinib in Participants With Epidermal Growth Factor Receptor (EGFR) Mutation Positive Advanced Non-Small Cell Lung Cancer (NSCLC)

Phase 1/2 Completed

29 enrolled 53 charts

Carcinoma, Non-Small-Cell Lung

NCT05862194 2023-08-22

Retrospective, External Comparator Study of Lazertinib as the 2nd-Line Treatment in Patients With EGFR Mutation+ NSCLC

Carcinoma, Non-Small-Cell Lung